Tranexamic Acid in Reverse Total Shoulder Arthroplasty

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 13% of the time (1,012 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: therapysurgerypostoperativecoronaryheart
  Phrases that lowered it: blooddiseasesoral1220
• Sponsor's past termination rate: 40% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Keywords listed: 22 (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Phase: 2/3 (lowers risk) · Design
• Drug's FAERS reports with a death: 24.3% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Sponsor's past trials: 20 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial NCT06920264 · started 2021 · scored riskier than 24% of active trials completed
• Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery NCT01199627 · started 2011 · scored riskier than 10% of active trials completed
• Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty NCT02393963 · started 2015 · scored riskier than 12% of active trials completed
• Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA NCT01940692 · started 2014 · scored riskier than 18% of active trials completed
• Effect on Post-operative Pain of Tranexamic Acid Injection During Shoulder Surgery NCT05302986 · started 2023 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.